Search

Taurine

[L1058] The supplements containing taurine were FDA approved by 1984 and they are hypertonic injections composed by cristalline amino acids.[FDA label] … [A31396] This conditional amino acid can be either be manufactured by the body or obtained in the diet mainly by the consumption of fish and meat.

Macimorelin

Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution. … More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels

Imdevimab

Casirivimab and imdevimab are investigational recombinant human IgG1 monoclonal antibodies that, at this time, are not officially approved by the FDA. … [A221495] On November 21, 2020, the FDA authorized emergency approval of REGN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older.

Sodium phosphate, dibasic

Liothyronine

[T457] The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956.[L5578]

Sutilain

[T169] Sutilain was developed by Abbott and FDA approved on June 12, 1969. It is currently discontinued.[L2368]

Aflibercept

[L47976] An aflibercept biosimilar, Yesafili, was approved for use in the EU in September 2023. … [A261130,L47915] Ziv-aflibercept, under the brand name Zaltrap, was developed as an intravenous injection for the treatment of metastatic colorectal cancer, and it was approved by the FDA and EMA in

Tagraxofusp

[A253762, A253887, L43702] Tagraxofusp received its first global approval by the FDA on December 21, 2018 as the first FDA-approved treatment for blastic plasmacytoid dendritic cell neoplasm, which is … It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_.

Fluocinolone acetonide

[T358] This type of device containing fluocinolone acetonide was developed by Taro Pharmaceuticals and approved by FDA in May 2016.[L4676]

Selinexor

[L10145] The FDA approved Selinexor in June 2019. … [L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant.